Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 6/20 | 0.51 |
| ▸ | LGMN | Q99538 | 3/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21293859 | 1.00 | CTSK (0.53) | CTSKSYKPSMB1BACE1LGMN | |
| SCHEMBL30902906 | 0.93 | REN (0.51) | CTSKSYKPSMB1BACE1PSMB5 | |
| SCHEMBL6078490 | 0.90 | SYK (0.56) | CTSKSYKPSMB1PSMB5ADORA3 | |
| SCHEMBL6078485 | 0.90 | SYK (0.56) | CTSKSYKPSMB1PSMB5ADORA3 | |
| SCHEMBL10931168 | 0.90 | CTSK (0.51) | CTSKSYKPSMB1BACE1PSMB5 | |
| SCHEMBL10932799 | 0.89 | PSMB5 (0.53) | CTSKSYKPSMB1BACE1PSMB5 | |
| SCHEMBL24992811 | 0.88 | MME (0.59) | CTSKPSMB1LGMNPSMB5REN | |
| SCHEMBL20677213 | 0.88 | MME (0.59) | CTSKPSMB1LGMNPSMB5REN | |
| SCHEMBL19384748 | 0.88 | MME (0.59) | CTSKPSMB1LGMNPSMB5REN | |
| SCHEMBL14371944 | 0.88 | MME (0.59) | CTSKPSMB1LGMNPSMB5REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | CTSK 1911/4885SYK 2335/4885PSMB1 755/4885 |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | CTSK 1911/4885SYK 2335/4885PSMB1 755/4885 |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | CTSK 1911/4885SYK 2335/4885PSMB1 755/4885 |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | CTSK 1911/4885SYK 2335/4885PSMB1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.